Cocrystal Pharma Advances Oral Norovirus Drug Candidate with Phase 1b Data Presentation at ICAR 2026 — Cocrystal Pharma, Inc.

Event summary

Cocrystal Pharma will present Phase 1 data and updates from an ongoing Phase 1b study for its oral norovirus protease inhibitor CDI-988 at ICAR 2026, held April 27–May 1 in Prague.
CDI-988 is the first oral antiviral drug candidate developed for both prevention and treatment of norovirus infections.
The Phase 1b challenge study is being conducted at Emory University School of Medicine to evaluate CDI-988 as a prophylactic and therapeutic option.
Norovirus causes an estimated 200,000 deaths worldwide annually with a societal cost of approximately $60 billion.

The big picture

Cocrystal Pharma’s presentation at ICAR 2026 highlights the strategic importance of developing antiviral therapies for norovirus, a highly contagious virus with significant global health and economic impacts. The absence of approved treatments creates a clear market opportunity, but success will depend on demonstrating efficacy and safety in clinical trials. CDI-988’s potential as a broad-spectrum antiviral could further enhance its value proposition if proven effective against other viral pathogens.

What we're watching

Clinical Progress: The pace at which CDI-988 advances through Phase 1b and potential transition to later-stage trials will determine its viability as a norovirus treatment.
Market Need: Whether Cocrystal can capitalize on the lack of approved antiviral therapies or vaccines for norovirus, which presents an immediate market need.
Broad-Spectrum Potential: How CDI-988's pan-viral protease inhibitor mechanism could expand its application beyond norovirus to other viral infections like coronaviruses.